TEZEPELUMAB
Information current as at: 1 June 2025
PBAC meeting date: July 2022
Submission Details
- Brand name:
-
- Tezspire®
- Pharmaceutical company:
- AstraZeneca Pty Ltd
- Condition/indication:
(therapeutic use) -
- Asthma
- PBAC Submission type:
- New PBS listing (Category 2)
- Comment:
- Sponsor has subsequently withdrawn their application
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2022 PBAC meeting
-
Opportunity for consumer comment: - Not applicable
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a537
Page last updated: 02 May 2024